<DOC>
	<DOC>NCT00244127</DOC>
	<brief_summary>To evaluate the safety and efficacy of R-COMP in elderly patients with advanced aggressive NHL. Myocet (non-pegylated liposomal doxorubicin) replaces conventional doxorubicin in the R-CHOP regimen.</brief_summary>
	<brief_title>Open Label, Single Arm, Phase II Study Using R-COMP in Elderly Patients With Aggressive NHL.</brief_title>
	<detailed_description>To evaluate the duration of remission, disease free survival and 2-year survival of R-COMP in first line therapy of elderly patients with advanced aggressive NHL. To evaluate the tolerability of R-COMP in first line therapy of elderly patients with advanced aggressive NHL.</detailed_description>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Aggression</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Diffuse Large BCell Lymphoma (DLBCL), and their morphologic variants and subtypes, i.e. Centroblastic lymphoma, Immunoblastic lymphoma, Tcell rich/Bcell lymphoma, anaplastic large Bcell lymphoma, mediastinal (thymic) large Bcell lymphoma; Primary diffuse large Bcell lymphoma of MALT (incorrectly defined as highgrade MALT lymphoma); Marginal zone Bcell lymphoma with coexisting areas of DLBCL; Age of ≥60 years; Clinical stage at diagnosis: I A bulky – IV B; CD20 positivity; Serum negativity for HbsAg and HCV except for those with no sign of active viral replication, assessed by HCVRNA copies; Absolute neutrophil count (ANC) ≥1.5x109/L, and platelet count ≥100x109/L (unless both are attributed directly to bone marrow involvement by lymphoma or autoimmune disease secondary to lymphoma); Serum creatinine ≤130μM/L, serum bilirubin ≤2.5xULN aspartate aminotransferase (AST/GOT), ≤2.5xULN alanine aminotransferase (ALT/GPT) ≤2.5xULN, and alkaline phosphatase ≤4 times the upper limit of normal (unless the increase is attributed directly to the presence of tumour by the Investigator) Left ventricular ejection fraction (LVEF) ≥50%; ECOG performance status 02; At least one measurable lesion is mandatory; Written informed consent given at time of registration; Males and females (both males and females of childbearing potential must agree to use adequate contraception for the duration, and for 3 months after the completion, of the treatment). Clinical stage I nonbulky, or CS IIA with less than three sites of disease involved (patients with stage IIB are eligible, regardless of the number of sites involved); Tumour involvement of CNS; Indolent lymphoma transformed in more aggressive histological type, even if never previously treated; Mantle Cell Lymphoma, Peripheral T cell Lymphoma and their variants; Aggressive nonHodgkin’s lymphoma in transplanted patient; Clinically significant secondary cardiovascular disease, e.g. uncontrolled hypertension, (resting diastolic blood pressure &gt;115 mmHg), uncontrolled multifocal cardiac arrhythmias, symptomatic angina pectoris or congestive cardiac failure NYHA class IIIIV; Evidence of any severe active acute or chronic infection; Concurrent malignancy or history of other malignancy, except basal cell carcinoma of the skin (BCC) and insitu cervical carcinoma (CIN) / Myelodysplastic syndrome; HbsAg, HIVpositive, or HCVRNApositive patients; Inability to comply with study procedures; Prior CNS lymphoma; Prior radiation to nonCNS lymphoma mass(es) as a treatment for lymphomas; History of allergic reaction to anthracyclines, eggs, and egg products or known sensitivities, or history of unusual reaction, to other components of, or treatments similar to, the investigational treatment regimen; Presence of other medication that may interfere with study treatment or the action of the investigational product or confuse the assessment of study results Pregnant women or nursing mothers; Participation in an investigational drug study within 4 weeks prior to study entry.</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2005</verification_date>
</DOC>